Treatment options for hyponatremia in heart failure

Congestive Heart Failure
Steven R Goldsmith

Abstract

Hyponatremia is independently associated with adverse outcomes in patients with congestive heart failure (CHF). The primary cause of hyponatremia in CHF is the inappropriate secretion of the antidiuretic hormone arginine vasopressin (AVP). The binding of AVP to V(2) receptors in the renal collecting duct promotes water retention, a process that can lead to dilutional hyponatremia as well as increased ventricular preload. Conventional treatment of hyponatremia in CHF is largely based on water restriction, which is neither effective nor well-tolerated. V(2)- and dual V(1a)/V(2)-receptor antagonists offer physiologically based treatment for dilutional hyponatremia. Clinical trials in patients with hyponatremia including those with CHF using both selective and nonselective vasopressin antagonists have demonstrated the effectiveness and safety of these agents in correcting this common electrolyte abnormality.

References

Aug 1, 1989·The Journal of Clinical Investigation·A T HirschM A Creager
Aug 1, 1986·The American Journal of Cardiology·S R GoldsmithA W Cowley
Jun 1, 1983·Journal of the American College of Cardiology·S R GoldsmithJ N Cohn
Apr 1, 1984·The Journal of Clinical Endocrinology and Metabolism·W PruszczynskiJ Acar
Jan 1, 1982·The American Journal of Medicine·G A RieggerK Kochsiek
Jul 30, 1981·The New England Journal of Medicine·V L SzatalowiczR W Schrier
Feb 23, 1999·Advances in Experimental Medicine and Biology·P S ChanW Spinelli
Mar 12, 1999·Journal of the American Society of Nephrology : JASN·S NielsenD Marples
Jul 1, 1999·Clinical and Experimental Pharmacology & Physiology·Y TomuraK Honda
Jan 14, 2000·Journal of Cardiac Failure·S R Goldsmith
Jul 6, 2000·The Journal of Clinical Investigation·J E KaufmannU M Vischer
Mar 28, 2002·JAMA : the Journal of the American Medical Association·Michael S CuffeUNKNOWN Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigato
Aug 30, 2002·Journal of Molecular Endocrinology·J G Verbalis
Apr 29, 2004·JAMA : the Journal of the American Medical Association·Mihai GheorghiadeUNKNOWN Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators
Jan 25, 2006·The American Journal of Medicine·Benoit RenneboogGuy Decaux
Nov 16, 2006·The New England Journal of Medicine·Robert W SchrierUNKNOWN SALT Investigators
Mar 27, 2007·JAMA : the Journal of the American Medical Association·Marvin A KonstamUNKNOWN Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators
Aug 1, 2007·American Journal of Nephrology·David ZeltserUNKNOWN Conivaptan Study Group

❮ Previous
Next ❯

Citations

Oct 6, 2016·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Hideto KawarataniHitoshi Yoshiji

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2021 Meta ULC. All rights reserved